Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы

Калмамбетова Гульмира Исмаиловна, к.м.н., зав. национальной референс лаборатории Национального Центра Фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кадыров Абдуллаат Саматович, д.м.н., профессор, директор Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика
Сыдыкова Мээрбубу Мисировна, лабораторный специалист национальной референс лаборатории Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика

Мойдунова Нестан Кубанычбековна, к.м.н., ассистент кафедры фтизиатрии КГМА им. И.К.Ахунбаева, Бишкек, Кыргызская Республика

PDF (RUS)

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К. Молекулярная эпидемиология туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2, с.86- 91. https://dx.doi.org/10.51350/zdravkg2022621186

Kalmambetova Gulmira Ismailovna, Ph.D., Head of the National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Kadyrov Abdullaat Samatovich, MD, Professor, Director of the National Center for Phthisiology at the Ministry of Health, Bishkek, Kyrgyz Republic

Sydykova Meerbubu Misirovna, laboratory specialist, National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Moidunova Nestan Kubanychbekovna, Ph.D., Assistant, Department of Phthisiology, KSMA named after I.K.Akhunbaeva, Bishkek, Kyrgyz Republic

PDF (RUS)

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Kalmambetova G.I.,Kadyrov A.S.,Sydykova M.M.,Moidunova N.K. Molecular epidemiology of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 2, pp. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186

Калмамбетова Гулмира Исмаиловна, медицина илимдеринин кандидаты,  Республикалык рефенс лаборатория Улуттук фтизиатрия борборунун болум башчысы, Бишкек, Кыргыз Республикасы

Кадыров Абдуллаат Саматович, медицина илимдеринин доктору,  Улуттук фтизиатрия борбору мудуру, Бишкек, Кыргыз Республикасы

Сыдыкова Мээрбубу Мисировна, лабораториялык адис, Республикалык рефенс лаборатория Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Мойдунова Нестан Кубанычбекова, медицина илимдеринин кандидаты,  И. К. Ахунбаева атындагы Кыргыз мамлекеттик медициналык академиясынын фтизиатрия кафедрасынын жардамчысы, Бишкек, Кыргыз Республикасы

PDF (RUS)

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы. Кыргызстандын саламаттык сактоо 2022, no 2, б. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186